

(FILE 'HOME' ENTERED AT 13:06:45 ON 25 JUN 2004)

FILE 'CAPLUS, EMBASE, SCISEARCH, MEDLINE, USPATFULL' ENTERED AT 13:09:17
ON 25 JUN 2004

```
L1      0 FILE CAPLUS
L2      0 FILE EMBASE
L3      0 FILE SCISEARCH
L4      0 FILE MEDLINE
L5      0 FILE USPATFULL
TOTAL FOR ALL FILES
L6      0 S "SYNDROMES OR SYMPTOMS OR SIGNALS" "PRIOR OR BEFOR" MIGRAINE
L7      0 FILE CAPLUS
L8      0 FILE EMBASE
L9      0 FILE SCISEARCH
L10     0 FILE MEDLINE
L11     0 FILE USPATFULL
TOTAL FOR ALL FILES
L12     0 S "SYNDROMES OR SYMPTOMS OR SIGNALS" AND "PRIOR OR BEFORE" AND
L13     3 FILE CAPLUS
L14     27 FILE EMBASE
L15     8 FILE SCISEARCH
L16     27 FILE MEDLINE
L17     38 FILE USPATFULL
TOTAL FOR ALL FILES
L18     103 S PRODROM? AND MIGRAINE ATTACK
L19     9 FILE CAPLUS
L20     39 FILE EMBASE
L21     28 FILE SCISEARCH
L22     34 FILE MEDLINE
L23     215 FILE USPATFULL
TOTAL FOR ALL FILES
L24     325 S (SYNDROMES OR SYMPTOMS OR SIGNALS) AND (PRIOR OR BEFORE) AND
L25     27 FILE CAPLUS
L26     253 FILE EMBASE
L27     188 FILE SCISEARCH
L28     232 FILE MEDLINE
L29     4452 FILE USPATFULL
TOTAL FOR ALL FILES
L30     5152 S (SYNDROMES OR SYMPTOMS OR SIGNALS) AND (PRIOR OR BEFORE) AND
L31     5 FILE CAPLUS
L32     172 FILE EMBASE
L33     101 FILE SCISEARCH
L34     24 FILE MEDLINE
L35     105 FILE USPATFULL
TOTAL FOR ALL FILES
L36     407 S (SYNDROMES OR SYMPTOMS OR SIGNALS) (100A) (PRIOR OR BEFORE) (
L37     3 FILE CAPLUS
L38     27 FILE EMBASE
L39     8 FILE SCISEARCH
L40     27 FILE MEDLINE
L41     38 FILE USPATFULL
TOTAL FOR ALL FILES
L42     103 S PRODROM? AND L16
L43     1 FILE CAPLUS
L44     4 FILE EMBASE
L45     1 FILE SCISEARCH
L46     0 FILE MEDLINE
L47     24 FILE USPATFULL
TOTAL FOR ALL FILES
L48     30 S PRODROM? AND L36
```

=> d 147 1-24 ib

(FILE 'HOME' ENTERED AT 13:56:38 ON 25 JUN 2004)

FILE 'EMBASE, SCISEARCH, MEDLINE, USPATFULL' ENTERED AT 13:56:54 ON 25 JUN 2004

```
L1      201 FILE EMBASE
L2      130 FILE SCISEARCH
L3      163 FILE MEDLINE
L4      15 FILE USPATFULL
TOTAL FOR ALL FILES
L5      509 S PRODROM? (10A) (DETERMIN? OR TEST? OR PROGNOS? OR DIAGNOS? )
L6      3 FILE EMBASE
L7      2 FILE SCISEARCH
L8      1 FILE MEDLINE
L9      1 FILE USPATFULL
TOTAL FOR ALL FILES
L10     7 S L5 AND MIGRAINE
L11     0 FILE EMBASE
L12     0 FILE SCISEARCH
L13     0 FILE MEDLINE
L14     0 FILE USPATFULL
TOTAL FOR ALL FILES
L15     0 S ((DETERMIN? OR FIND? OR PREDICT? OR ANTICIPAT?) (3W) PRODROM?
L16     30 FILE EMBASE
L17     22 FILE SCISEARCH
L18     29 FILE MEDLINE
L19     1 FILE USPATFULL
TOTAL FOR ALL FILES
L20     82 S ((DETERMIN? OR FIND? OR PREDICT? OR ANTICIPAT?) (3W) PRODROM?
L21     7 FILE EMBASE
L22     4 FILE SCISEARCH
L23     5 FILE MEDLINE
L24     0 FILE USPATFULL
TOTAL FOR ALL FILES
L25     16 S L20 AND (HEADACH? OR PAIN OR MIGRAIN?)
```

=>

(FILE 'HOME' ENTERED AT 11:52:33 ON 25 JUN 2004)

FILE 'USPATFULL, CAPLUS' ENTERED AT 11:53:11 ON 25 JUN 2004

L1 1 FILE USPATFULL
L2 0 FILE CAPLUS
TOTAL FOR ALL FILES
L3 1 S MIGRAINE AND PREDICT AND TEST AND (ANAM OR (AUTOMATED (3A) AS
L4 438 FILE USPATFULL
L5 0 FILE CAPLUS
TOTAL FOR ALL FILES
L6 438 S MIGRAINE AND PREDICT AND TEST AND (COGNITIVE)
L7 699 FILE USPATFULL
L8 5 FILE CAPLUS
TOTAL FOR ALL FILES
L9 704 S MIGRAINE AND PREDICT? AND TEST AND (COGNITIVE)
L10 17 FILE USPATFULL
L11 2 FILE CAPLUS
TOTAL FOR ALL FILES
L12 19 S MIGRAINE (1S) TEST (1S) (COGNITIVE)
L13 92 FILE USPATFULL
L14 30 FILE CAPLUS
TOTAL FOR ALL FILES
L15 122 S PREDICT? (1S) MIGRAINE
L16 84 FILE USPATFULL
L17 10 FILE CAPLUS
TOTAL FOR ALL FILES
L18 94 S L15 AND (TEST? OR SCESS?)
L19 13 FILE USPATFULL
L20 12 FILE CAPLUS
TOTAL FOR ALL FILES
L21 25 S ANAM OR (AUTOMATED NEUROPSYCHOLOGICAL ASSESSMENT METRIC?)
L22 1 FILE USPATFULL
L23 0 FILE CAPLUS
TOTAL FOR ALL FILES
L24 1 S L21 AND MIGRAINE
L25 3 FILE USPATFULL
L26 3 FILE CAPLUS
TOTAL FOR ALL FILES
L27 6 S L21 AND COGNITIVE
L28 0 FILE USPATFULL
L29 0 FILE CAPLUS
TOTAL FOR ALL FILES
L30 0 S D 1-6 HIT, AN, PI
L31 51 FILE USPATFULL
L32 19 FILE CAPLUS
TOTAL FOR ALL FILES
L33 70 S MIGRAINE (30A) PREDICT?

FILE 'EMBASE, SCISEARCH, MEDLINE, USPATFULL, CAPLUS' ENTERED AT 12:14:15
ON 25 JUN 2004

L34 1952112 FILE EMBASE
L35 2353388 FILE SCISEARCH
L36 2148720 FILE MEDLINE
L37 2944863 FILE USPATFULL
L38 3168007 FILE CAPLUS
TOTAL FOR ALL FILES
L39 12567090 S SYNDROM? OR SYMPTOM? OR CHARACTERISTIC? OR FEATURE? OR CONDIR
L40 143 FILE EMBASE
L41 86 FILE SCISEARCH
L42 77 FILE MEDLINE
L43 156 FILE USPATFULL
L44 10 FILE CAPLUS
TOTAL FOR ALL FILES
L45 472 S (MIGRAINE OR MIGRAIN) (2S) (PREDICT? OR ANTICIPAT?) (2S) L39

```

L46      143 FILE EMBASE
L47      85 FILE SCISEARCH
L48      67 FILE MEDLINE
L49     156 FILE USPATFULL
L50      9 FILE CAPLUS
TOTAL FOR ALL FILES
L51     460 S (MIGRAINE OR MIGRAIN ) (2S) (PREDICT? OR ANTICIPAT?) (1S) L39
L52      2 FILE EMBASE
L53      0 FILE SCISEARCH
L54      0 FILE MEDLINE
L55     12 FILE USPATFULL
L56      0 FILE CAPLUS
TOTAL FOR ALL FILES
L57     14 S L51 AND (PROGNOS? OR DIAGNO?) AND (COGNITIVE)
L58      0 FILE EMBASE
L59      0 FILE SCISEARCH
L60      0 FILE MEDLINE
L61      0 FILE USPATFULL
L62      0 FILE CAPLUS
TOTAL FOR ALL FILES
L63      0 S L51 AND (PROGNOS? OR DIAGNO?) AND (TEST OR ASSESS? ) AND (PRE
L64      7 FILE EMBASE
L65      5 FILE SCISEARCH
L66      2 FILE MEDLINE
L67     119 FILE USPATFULL
L68      1 FILE CAPLUS
TOTAL FOR ALL FILES
L69     134 S L51 AND (TEST OR ASSESS? ) AND (PREVENT? OR  PROPHYL?)
L70     24 FILE EMBASE
L71     119 FILE SCISEARCH
L72     26 FILE MEDLINE
L73     13 FILE USPATFULL
L74     12 FILE CAPLUS
TOTAL FOR ALL FILES
L75     194 S L21
L76      0 FILE EMBASE
L77      0 FILE SCISEARCH
L78      0 FILE MEDLINE
L79      0 FILE USPATFULL
L80      0 FILE CAPLUS
TOTAL FOR ALL FILES
L81      0 S L75 AND MIGRAINE AND (DIAGN? OR PROGNO?)
L82      2 FILE EMBASE
L83      3 FILE SCISEARCH
L84      2 FILE MEDLINE
L85      1 FILE USPATFULL
L86      0 FILE CAPLUS
TOTAL FOR ALL FILES
L87      8 S L75 AND MIGRAINE
      SAVE ALL L09575277B/L

```

=>

ETD [0050] The **ANAM** Running Memory Test and the KCPT were the primary tests for measuring vigilance. Useable data for the **ANAM** Running Memory Test was obtained for only 28 subjects. Five of the subjects were not using the correct key to respond and two subjects had response times (at all 3 sessions) that were extreme outliers. For the remaining 14 NADH and 14 placebo subjects, there was a baseline difference in reaction time ($P=0.005$). However, the groups did not differ at baseline with respect to number of items completed or accuracy. The Group x Session interaction is significant for accuracy ($P=0.036$). Accuracy for placebo subjects dropped from 95% at baseline to 91% at the AM and PM testing. For NADH subjects Running Memory accuracy scores remained stable across all three sessions at approximately 96%. These results can be seen graphically in FIG. 1.

DETD [0052] The **ANAM** Math Test and the Shifting Attention Test: Instruction Condition were the primary tests for measuring the working memory of the subjects. There were no baseline group differences on the Shifting Attention Test: Instruction Condition. The Group x Session effect was significant ($P<0.05$). Analysis of contrasts shows that subjects in the NADH group correctly completed 13.2 more problems per minute at the AM test vs. baseline, compared to 6.8 more problems correctly completed per minute for the placebo group. As can be seen in FIG. 2, for the placebo subjects accuracy dropped from 93% at baseline to 91% at the AM test, while for NADH subjects performance improved from 92.5% at baseline to 95% at the AM test session. On the **ANAM** Math Test, the Group x Session effect approached significance for the measure of throughput ($P<0.07$). For subjects in the NADH group, there was a 15% improvement relative to baseline at the AM test and an 11% improvement at the PM test. By comparison, subjects in the placebo group showed a 6% improvement at the AM test and a 4% improvement at the PM test. The mean difference between groups was not significant ($P<0.08$).

DETD [0057] The results of these examples indicate that stabilized NADH had a beneficial effect on treating the effects of sleep deprivation and jet lag. NADH appears to mitigate the effects of jet lag on **cognitive** and psychomotor functions considered particularly sensitive to sedation, such as vigilance, working memory, visuomotor tracking and divided attention. In addition, NADH showed a trend to reduce the number of subjects experiencing self-reported sleepiness.

DETD [0059] On measures of vigilance there was a notable increase in lapses of attention without NADH treatment, as reflected by omission errors on the two continuous performance tests (KCPT and **ANAM** Running Memory Test). These lapses of attention were most evident in the morning following the flight. By the afternoon, only 14% of NADH subjects had omission errors on the KCPT and mean accuracy on the Running Memory Test was 96%. In contrast, 37% of placebo subjects made omission errors on the KCPT and the mean accuracy on the Running Memory Test was 91%.

DETD [0060] NADH also appears to have a protective effect on working memory, which is the ability to temporarily hold information in mind and to perform a mental operation on the information. On the morning test, subjects who received NADH showed an improvement in accuracy on the Shifting Attention Test: Instruction Condition. In sharp contrast, accuracy dropped for subjects in the placebo condition. On a second measure of working memory, the **ANAM** Math Test, there was also a trend for better performance with NADH treatment.

DETD [0066] Sublingual stabilized NADH appears to be an effective treatment for the effects of jet lag and sleep deprivation on cognition and sleepiness. In the current examples, subjects receiving NADH showed less reduction of **cognitive** functioning and were more likely to be functioning at their baseline (pre-flight) levels than subjects who received placebo.

AN 2003:29830 USPATFULL
PI US 2003021772 A1 20030130

L33 ANSWER 68 OF 70 CAPLUS COPYRIGHT 2004 ACS on STN
AB A review, with 26 refs., discussing the relevance of animal models of **migraine** to the human disease and exploring the validity of such models by considering their **predictive** value, established when drugs that show activity in an animal model are shown to be clin. effective in **migraine** patients. Exptl. models used to identify and develop sumatriptan as a novel, effective antimigraine drug are discussed.
AN 1995:956366 CAPLUS
DN 124:75252

L33 ANSWER 66 OF 70 CAPLUS COPYRIGHT 2004 ACS on STN

AB The anti-migraine compound, sumatriptan, has been shown to have substantial affinity for the cloned human 5-HT_{1F} receptor suggesting that, in addition to 5-HT_{1B}/5-HT_{1D} receptor subtypes, the 5-HT_{1F} receptor may be a therapeutic target for the treatment of migraine. Several investigators have used the guinea pig plasma extravasation model to evaluate potential anti-migraine drugs. Since species differences in the pharmacol. of serotonin receptors are well known, the authors compared the pharmacol. profiles of the cloned human and guinea pig 5-HT_{1F} receptors to validate the usefulness of the in vivo model in **predicting** anti-migraine activity of compds. targeted for humans. The authors have cloned the guinea pig 5-HT_{1F} by homol. to the human 5-HT_{1F} receptor and evaluated its pharmacol. profile using radioligand binding assays. The cloned guinea pig 5-HT_{1F} gene exhibited 94% amino acid identity to the corresponding human homolog. High affinity (K_d .apprx. 10 nM) [³H]5-HT binding was detected to membranes obtained from Cos-7 cells transiently expressing the guinea pig 5-HT_{1F} receptor. The cloned guinea pig receptor displayed typical 5-HT_{1F} receptor pharmacol. with the following rank order of binding affinities: 5-HT > sumatriptan > 1-NP = DHE > α -Me 5-HT > metergoline > methiothepin > 5-CT. The pharmacol. profiles of the clones guinea pig and human 5-HT_{1F} receptors were very similar as reflected by the high correlation (R² = 0.72, slope = 0.76) observed between the binding affinities of compds. for these two species homologs. In situ hybridization studies in guinea pig tissue revealed 5-HT_{1F} receptor mRNA expression in the neurons of the trigeminal ganglion, suggesting that the 5-HT_{1F} receptor may play a role in the presynaptic inhibition of neuropeptide release at the level of the intracranial vasculature, thereby blocking the development of neurogenic inflammation. Dorsal root ganglion cells also moderately expressed the 5-HT_{1F} transcripts. The localization of the 5-HT_{1F} receptor to areas involved in the mediation and transfer of nociceptive information implies a role for this receptor in pain processing. These findings indicate that a selective 5-HT_{1F} agonist may be a novel approach to treat migraine.

AN 1997:430378 CAPLUS

DN 127:131365

L33 ANSWER 65 OF 70 CAPLUS COPYRIGHT 2004 ACS on STN

AB A review discussion, with no refs., with intention to perform, in a purely speculative way, a clinician's subjective evaluation of the new 5-HT_{1D} agonists in an attempt to **predict** their future therapeutic value in the acute treatment of **migraine**. The ideal 5-HT₁ agonist should have 5-HT_{1Dα} and 5-HT_{1Dβ} agonistic properties, be highly potent, have acceptable bioavailability independently of the route of administration, penetrate the blood-brain barrier, have few active metabolites, be well-tolerated and cardiovascularly safe, and be administered in such way that its beneficial effects are optimally utilized.

AN 1997:656567 CAPLUS

DN 127:302792

L33 ANSWER 63 OF 70 CAPLUS COPYRIGHT 2004 ACS on STN
TI **Prediction** of **migraine** attacks using a slow cortical
potential, the contingent negative variation
AN 1998:723196 CAPLUS

L69 ANSWER 11 OF 134 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

AB 85 patients with **migraine** without aura and 20 healthy individuals were examined between the attacks, before the attack, during and after it (1-2 days). The examination included clinical-neurological analysis; psychological Spilberger's and Beck's **tests**, scale of alexithymia and complex algescic questionnaire; recording of the **conditional** negative wave; determination of nociceptive flexor reflex; recording of trigeminal evoked potentials; spectral analysis of the heart's rhythms; polysomnographic study. Psychophysiological pattern **characteristic** for all the patients was established. Psychological and neurophysiological parameters changed synchronously in the periods before the attack, during and after it. Before the migraineous attack a specific pathologic integration increased and presented maximally (the activity of antinociceptive system weakens anxiety increased, tension of catecholaminergic systems grew, hyperactivity in trigeminal sphere elevated, tolerance to the pain decreased). A clear tendency to the reversibility of these changes was observed after an attack. A dynamics revealed in the psychophysiological pattern could serve as a **predictor** of a migraineous attack and open some perspectives for **prophylaxis** of the algescic attack.

AN 2001:102729 SCISEARCH

L87 ANSWER 7 OF 8 MEDLINE on STN
 AN 2001072675 MEDLINE
 DN PubMed ID: 10971662
 TI A pilot study to measure cognitive efficiency during **migraine**.
 AU Farmer K; Cady R; Bleiberg J; Reeves D
 CS Headache Care Center, Springfield, MO 65804, USA.
 SO Headache, (2000 Sep) 40 (8) 657-61.
 Journal code: 2985091R. ISSN: 0017-8748.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200101
 ED Entered STN: 20010322
 Last Updated on STN: 20010322
 Entered Medline: 20010104
 AB BACKGROUND AND OBJECTIVES: The measurement of cognitive efficiency during **migraine** has produced conflicting results primarily due to the types of tests used. The objectives of this pilot study were two-fold: to measure cognitive efficiency during **migraine**, compared to a **migraine**-free period, and to evaluate the effects of therapy with a 5-HT₁ agonist (sumatriptan injection, 6 mg) on the cognitive efficiency of migraineurs during a **migraine**. METHOD: The Headache Care Center-Automated Neuropsychological Assessment Metrics was administered to 10 migraineurs, three times without a **migraine**, once during a **migraine**, and three times after administration of sumatriptan injection (6 mg). RESULTS: The results demonstrated a significant drop in cognitive efficiency during **migraine** and recovery 15 minutes after therapeutic injection. CONCLUSIONS: This pilot study is the first to document a significant drop in cognitive functioning during **migraine** and recovery after administration of a **migraine**-specific medication.
 CT *Cognition
 Cognition: DE, drug effects
 Migraine: DT, drug therapy
 *Migraine: PX, psychology
 Neuropsychological Tests
 Pilot Projects
 Reference Values
 Serotonin Agonists: TU, therapeutic use
 Sumatriptan: TU, therapeutic use
 RN 103628-46-2 (Sumatriptan)
 CN 0 (Serotonin Agonists)

=>

=> d his

(FILE 'HOME' ENTERED AT 11:52:33 ON 25 JUN 2004)

FILE 'USPATFULL, CAPLUS' ENTERED AT 11:53:11 ON 25 JUN 2004

L1 1 FILE USPATFULL
L2 0 FILE CAPLUS
TOTAL FOR ALL FILES
L3 1 S MIGRAINE AND PREDICT AND TEST AND (ANAM OR (AUTOMATED (3A) AS
L4 438 FILE USPATFULL
L5 0 FILE CAPLUS
TOTAL FOR ALL FILES
L6 438 S MIGRAINE AND PREDICT AND TEST AND (COGNITIVE)
L7 699 FILE USPATFULL
L8 5 FILE CAPLUS
TOTAL FOR ALL FILES
L9 704 S MIGRAINE AND PREDICT? AND TEST AND (COGNITIVE)
L10 17 FILE USPATFULL
L11 2 FILE CAPLUS
TOTAL FOR ALL FILES
L12 19 S MIGRAINE (1S) TEST (1S) (COGNITIVE)
L13 92 FILE USPATFULL
L14 30 FILE CAPLUS
TOTAL FOR ALL FILES
L15 122 S PREDICT? (1S) MIGRAINE
L16 84 FILE USPATFULL
L17 10 FILE CAPLUS
TOTAL FOR ALL FILES
L18 94 S L15 AND (TEST? OR SSESS?)
L19 13 FILE USPATFULL
L20 12 FILE CAPLUS
TOTAL FOR ALL FILES
L21 25 S ANAM OR (AUTOMATED NEUROPSYCHOLOGICAL ASSESSMENT METRIC?)
L22 1 FILE USPATFULL
L23 0 FILE CAPLUS
TOTAL FOR ALL FILES
L24 1 S L21 AND MIGRAINE
L25 3 FILE USPATFULL
L26 3 FILE CAPLUS
TOTAL FOR ALL FILES
L27 6 S L21 AND COGNITIVE
L28 0 FILE USPATFULL
L29 0 FILE CAPLUS
TOTAL FOR ALL FILES
L30 0 S D 1-6 HIT, AN, PI
L31 51 FILE USPATFULL
L32 19 FILE CAPLUS
TOTAL FOR ALL FILES
L33 70 S MIGRAINE (30A) PREDICT?

FILE 'EMBASE, SCISEARCH, MEDLINE, USPATFULL, CAPLUS' ENTERED AT 12:14:15
ON 25 JUN 2004

L34 1952112 FILE EMBASE
L35 2353388 FILE SCISEARCH
L36 2148720 FILE MEDLINE
L37 2944863 FILE USPATFULL
L38 3168007 FILE CAPLUS
TOTAL FOR ALL FILES
L39 12567090 S SYNDROM? OR SYMPTOM? OR CHARACTERISTIC? OR FEATURE? OR CONDIT
L40 143 FILE EMBASE
L41 86 FILE SCISEARCH
L42 77 FILE MEDLINE
L43 156 FILE USPATFULL
L44 10 FILE CAPLUS

TOTAL FOR ALL FILES

L45 472 S (MIGRAINE OR MIGRAIN) (2S) (PREDICT? OR ANTICIPAT?) (2S) L39

L46 143 FILE EMBASE

L47 85 FILE SCISEARCH

L48 67 FILE MEDLINE

L49 156 FILE USPATFULL

L50 9 FILE CAPLUS

TOTAL FOR ALL FILES

L51 460 S (MIGRAINE OR MIGRAIN) (2S) (PREDICT? OR ANTICIPAT?) (1S) L39

L52 2 FILE EMBASE

L53 0 FILE SCISEARCH

L54 0 FILE MEDLINE

L55 12 FILE USPATFULL

L56 0 FILE CAPLUS

TOTAL FOR ALL FILES

L57 14 S L51 AND (PROGNOS? OR DIAGNO?) AND (COGNITIVE)

L58 0 FILE EMBASE

L59 0 FILE SCISEARCH

L60 0 FILE MEDLINE

L61 0 FILE USPATFULL

L62 0 FILE CAPLUS

TOTAL FOR ALL FILES

L63 0 S L51 AND (PROGNOS? OR DIAGNO?) AND (TEST OR ASSESS?) AND (PRE

L64 7 FILE EMBASE

L65 5 FILE SCISEARCH

L66 2 FILE MEDLINE

L67 119 FILE USPATFULL

L68 1 FILE CAPLUS

TOTAL FOR ALL FILES

L69 134 S L51 AND (TEST OR ASSESS?) AND (PREVENT? OR PROPHYL?)

L70 24 FILE EMBASE

L71 119 FILE SCISEARCH

L72 26 FILE MEDLINE

L73 13 FILE USPATFULL

L74 12 FILE CAPLUS

TOTAL FOR ALL FILES

L75 194 S L21

L76 0 FILE EMBASE

L77 0 FILE SCISEARCH

L78 0 FILE MEDLINE

L79 0 FILE USPATFULL

L80 0 FILE CAPLUS

TOTAL FOR ALL FILES

L81 0 S L75 AND MIGRAINE AND (DIAGN? OR PROGNO?)

L82 2 FILE EMBASE

L83 3 FILE SCISEARCH

L84 2 FILE MEDLINE

L85 1 FILE USPATFULL

L86 0 FILE CAPLUS

TOTAL FOR ALL FILES

L87 8 S L75 AND MIGRAINE

SAVE ALL L09575277B/L

L48 ANSWER 30 OF 30 USPATFULL on STN

DETD Individuals suffering a classic **migraine** attack experience some warning of impending pain. This **prodrome** or "aura" can take various forms, but most often involves visual or sensory phenomena (loss of part of the field. . . In other instances, the warning may be virtually subliminal; a person simply becomes aware that an attack is in progress **before symptoms** develop. The aura of a **migraine** normally starts between 15 and 60 minutes **prior** to the commencement of such **symptoms** as pain.

DETD It is desirable that administration of the β -adrenergic-blocking agent occur as soon as possible during a **migraine** attack. As **symptoms** persist and/or become more severe during an attack, they become less amenable to treatment. Consequently, it is desirable to commence administration **before** the **migraine** fully develops and especially within 30, more desirably 10, minutes of onset of aura.

DETD These graphs clearly reflect that, contrary to **prior** belief, propranolol can be utilized in other than a prophylactic manner to control **migraines**. Where the propranolol is promptly administered after aura, the normal increases in the severity of **symptoms** are not only interrupted, but there is a significant recovery from the **migraine** attack. Thus, properly administered, such a β -adrenergic-blocking agent may be utilized to successfully treat these headache **symptoms**.

AN 93:74331 USPATFULL

nt can also be administered in combination with a.

SUMM The phases of a **migraine** headache have been separated into the **prodrome**, aura and acute painful headache stages. The **prodrome** is the primary stage of a **migraine** attack characterized by an alteration of mood, energy or passive functions. This stage can occur for hours **before** the onset of the headache. The mood alterations include euphoria, loquaciousness, unprovoked apathy, depression, inertia, drowsiness, irritability, repetitive yawning, aggression. . . to various levels of sound (sonophobia). Nausea and vomiting, as well as paresthesias in the extremities, may also accompany these **symptoms**.

SUMM A variety of pharmacological agents has been employed in the **prior** art in attempting to treat individuals suffering from **migraine** headaches. The pharmacological agents previously used generally counteracted the **symptoms** of a **migraine** after, rather than **before**, occurrence of the acute **migraine** headache phase, specifically by antagonizing the effects of serotonin or its utilization at the brain stem and forebrain synapses.

SUMM . . . to provide a method of preventing or alleviating migraine headaches that can be carried out prior to or during the **prodrome** phase.

SUMM . . . to a patient a -pharmaceutically effective amount of a mast cell degranulation blocking agent just prior to or during the **prodrome** phase in the absence of an analgesic administered prior to the onset of the acute migraine phase.

DETD . . . that administration of mast cell blocking agents, especially those which interfere with the cell receptor activation mechanisms in the primary **prodromal** stage, will prevent or alleviate the onset of the two later stages in the migraine process.

DETD . . . analgesics, and often related to her menstrual cycle, was administered sublingually hydroxyzine in the form of the pamoate ester. Her **prodrome** was characterized by nausea and photophobia and typically lasted roughly 1/2 hour. During the **prodrome** of the migraine, she took 50 mg hydroxyzine pamoate sublingually in the absence of any other analgesic. In each and. . .

DETD . . . those four years by narcotic or non-narcotic analgesics, was administered hydroxyzine in the form of the pamoate ester sublingually. Her **prodrome** was shown by generalized malaise and photophobia and sonophobia, i.e., intolerance to intense light or sound, respectively. Her **prodrome** typically lasted one to two hours. During the **prodrome** of the migraine, she took 50 mg of hydroxyzine pamoate powder in an inert carrier sublingually in the absence of. . .

CLM What is claimed is:

. . . step of administering to a patient a pharmaceutically effective amount of a mast cell degranulation blocking agent only during the **prodrome** phase in the absence of an analgesic administered prior to the onset of the acute migraine phase.

AN 93:82846 USPATFULL|

DETD It will be appreciated by the routine practitioner that the **prodrome** phase of a condition of migraine occurs before aura and before severe or throbbing migraine pain. Frequently during **prodrome**, the migraine sufferer experiences mood changes, lethargy and tiredness. It will also be appreciated that migrainous aura, which is experienced. . . .

DETD In another embodiment of the present invention, the nonprescription APAP/ASA/CAF composition provides abortive relief of a migraine attack after the **prodrome** and/or aura phases and once migraine pain has developed. In accordance with this aspect of the invention, the analgesic combination. . . . nausea, photophobia, phonophobia and basic functional disabilities, that are further associated with migraine and migraine pain that occur after the **prodrome** phase.

DETD (e.g., Imitrex®, Glaxo-Wellcome), (see Example 9). Both sumatriptan and the APAP/ASA/CAF combination treatment of the present invention are capable of **prodromally** aborting migraine. The similarities in the effectiveness of sumatriptan and the APAP/ASA/CAF combination analgesic used according to the present invention. . . .

CLM What is claimed is:
. . . . selected from the group consisting of nausea, photophobia, phonophobia and functional disability, comprising administering to a human subject during the **prodrome** phase of the migraine attack a migraine abortive effective amount of a composition comprising a combination of acetaminophen, aspirin and. . . .

AN 1999:132801 USPATFULL|

d with **migraine** and **migraine** pain

that occur after the **prodrome** phase of a **migraine** headache. It would be a further benefit and advantage to have a remedy for the amelioration, relief, and/or removal of. . .

DETD . . . 2-3 mm/min (K. S. Lashley, 1941, Arch. Neurol. Psychiatry, 46:331-339). It has been suggested that spreading depression may underlie various **prodromes** that precede the onset of migraine headache, particularly visual aura (M. Lauritzen, 1994, Brain, 117:199-210). Clinical neurological migraine **prodromes** proceed in a temporal fashion that is correlated with the expected rate of spreading depression (M. Lauritzen and J. Olesen, . . .

DETD [0044] The foregoing suggests that spreading depression may both underlie the visual aura, and possibly other **prodromes**, that precede migraine and cause the ensuing migraine attack and accompanying pain (J. E. Hardebo, 1991, Headache, 25 31:213-221; J. . .

DETD [0090] Another embodiment of the present invention provides methods for treating or preventing **migraine** or **migraine** headache, or diseases similar, or mechanistically related to **migraine**, in a mammal, preferably humans, in need thereof. Treatment includes reduction, amelioration, suppression, or alleviation of **migraine** pain and/or its associated **symptoms** and characteristics. The method and KCNQ opener compounds utilized therein may also be efficacious in the treatment or prevention of **symptoms** associated with **migraine** prior to a full-blown **migraine** attack, as well as in the treatment of active **migraine** or **migraine** headache after onset.

AN 2002:236079 USPATFULL

L47 ANSWER 1 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2004:121147 USPATFULL
TITLE: Angiotensin II antagonists
INVENTOR(S): Schrader, Harald, Trondheim, NORWAY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004092563	A1	20040513
APPLICATION INFO.:	US 2002-311760	A1	20021218 (10)
	WO 2001-SE1379		20010615

	NUMBER	DATE
PRIORITY INFORMATION:	SE 2000-2353	20000622
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WHITE & CASE LLP, PATENT DEPARTMENT, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	459	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 2 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2004:7804 USPATFULL
TITLE: Pharmaceutical compositions for headache, migraine, nausea and emesis
INVENTOR(S): Barkan, Raphael, Zion, ISRAEL
Mirimsky, Alexander, Rehovot, ISRAEL
PATENT ASSIGNEE(S): MEDITOR PHARMACEUTICALS LTD., Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006044	A1	20040108
APPLICATION INFO.:	US 2003-382217	A1	20030305 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-IL817, filed on 30 Aug 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2001-144632	20010730
	US 2000-229812P	20000905 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WINSTON & STRAWN, PATENT DEPARTMENT, 1400 L STREET, N.W., WASHINGTON, DC, 20005-3502	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1454	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 3 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:300824 USPATFULL
TITLE: Prophylactic treatment of migraine
INVENTOR(S): Van Patten, Peter, Aurora, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003212050	A1	20031113
APPLICATION INFO.:	US 2003-363079	A1	20030227 (10)
	WO 2001-US26797		20010827

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul W Busse, Faegre & Benson, 2200 Wells Fargo Center,
90 South Seventh Street, Minneapolis, MN, 55402-3901
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 4 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:282328 USPATFULL
TITLE: Compositions and methods for rapid dissolving
formulations of dihydroergotamine and caffeine for the
treatment of migraine
INVENTOR(S): Cutler, Neal R., Los Angeles, CA, UNITED STATES
DiSanto, Anthony, Gobles, MI, UNITED STATES
PATENT ASSIGNEE(S): R.T. Alamo Ventures I, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198669	A1	20031023
APPLICATION INFO.:	US 2002-303455	A1	20021125 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-133855, filed on 26 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-899412, filed on 5 Jul 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1703		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L47 ANSWER 5 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:258406 USPATFULL
TITLE: Use of a vitamin combination for the treatment of
primary headaches
INVENTOR(S): Valletta, Giampiero, Ceprano, ITALY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181459	A1	20030925
APPLICATION INFO.:	US 2003-343853	A1	20030205 (10)
	WO 2001-IT388		20010720

	NUMBER	DATE
PRIORITY INFORMATION:	IT 2000-RM448	20000807
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 6 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2003:194067 USPATFULL
TITLE: Apparatus for directed intranasal administration of a
composition
INVENTOR(S): Levin, Bruce H., Merion, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003133877	A1	20030717
APPLICATION INFO.:	US 2002-218138	A1	20020812 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-737302, filed on 15 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-492946, filed on 27 Jan 2000, GRANTED, Pat. No. US 6491940 Continuation-in-part of Ser. No. US 1998-118615, filed on 17 Jul 1998, GRANTED, Pat. No. US 6432986		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-170817P	19991215 (60)
	US 1999-117398P	19990127 (60)
	US 1998-84559P	19980506 (60)
	US 1998-72845P	19980128 (60)
	US 1997-90110P	19970721 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKIN GUMP STRAUSS HAUER & FELD L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103-7013	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	4846	

L47 ANSWER 7 OF 24 USPATFULL on STN
 ACCESSION NUMBER: 2002:325709 USPATFULL
 TITLE: Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches
 INVENTOR(S): Levin, Bruce H., 241 S. 6th St., Philadelphia, PA, United States 19106

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6491940	B1	20021210
APPLICATION INFO.:	US 2000-492946		20000127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117398P	19990127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	George, Konata M	
LEGAL REPRESENTATIVE:	Akin, Gump, Strauss, Hauer & Feld, L.L.P.	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	4346	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 8 OF 24 USPATFULL on STN
 ACCESSION NUMBER: 2002:236079 USPATFULL
 TITLE: Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases
 INVENTOR(S): Dworetzky, Steven I., Middlefield, CT, UNITED STATES
 Gribkoff, Valentin K., Wallingford, CT, UNITED STATES
 Kinney, Gene G., Collegeville, PA, UNITED STATES
 Hewawasam, Piyasena, Middletown, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128277	A1	20020912
APPLICATION INFO.:	US 2002-75703	A1	20020214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269967P	20010220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, BRISTOL-MYERS SQUIBB COMPANY, Patent Department, P. O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1482	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 9 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:217274 USPATFULL

TITLE: Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers

INVENTOR(S): Frank-Kollman, Mary Theresa, 173 Egrets Way, Richmond Hill, GA, United States 31324

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440983	B1	20020827
APPLICATION INFO.:	US 2000-746135		20001221 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Gottlieb, Rackman & Reisman		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1,9,16		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	471		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 10 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:186139 USPATFULL

TITLE: Method for treating migraines

INVENTOR(S): Imanzahrai, Ashkan, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099060	A1	20020725
APPLICATION INFO.:	US 2002-37517	A1	20020104 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-593238, filed on 14 Jun 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-144973P	19990722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Kevin D. McCarthy, Esq., Hodgson Russ LLP, Suite 2000, One M&T Plaza, Buffalo, NY, 14203-2391	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	23	
LINE COUNT:	399	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 11 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2002:186138 USPATFULL
TITLE: Combination therapy for the treatment of migraine
INVENTOR(S): Saper, Joel, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099059	A1	20020725
APPLICATION INFO.:	US 2001-934276	A1	20010821 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-227350P	20000823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	416	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 12 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:172403 USPATFULL
TITLE: Migraine medicine and method of treating the same without caffeine
INVENTOR(S): Imanzahrai, Ashkan, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002091162	A1	20020711
APPLICATION INFO.:	US 2002-37516	A1	20020104 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-593238, filed on 14 Jun 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-144973P	19990722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Kevin D. McCarthy, Esq., Hodgson Russ LLP, Suite 2000, One M&T Plaza, Buffalo, NY, 14203-2391	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	2	
LINE COUNT:	473	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 13 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:88530 USPATFULL
TITLE: Pharmaceutical compositions containing tramadol for migraine
INVENTOR(S): Raber, Marc, Giessen, GERMANY, FEDERAL REPUBLIC OF Momberger, Helmut, Marburg, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): ASTA Medica AG, Dresden, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376550	B1	20020423
APPLICATION INFO.:	US 1999-247204		19990209 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spivack, Phyllis G.		
LEGAL REPRESENTATIVE:	Goodwin Proctor LLP		

NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 14 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2002:17314 USPATFULL
TITLE: Compositions, kits, and methods for inhibiting cerebral
neurovascular disorders and muscular headaches
INVENTOR(S): Levin, Bruce H., Merion, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010194	A1	20020124
APPLICATION INFO.:	US 2001-775724	A1	20010201 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-118615, filed on 17 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)
	US 1997-90110P	19970721 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3431	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 15 OF 24 USPATFULL on STN
ACCESSION NUMBER: 2001:237495 USPATFULL
TITLE: COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL
NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES
INVENTOR(S): LEVIN, BRUCE H., PHILADELPHIA, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055607	A1	20011227
	US 6432986	B2	20020813
APPLICATION INFO.:	US 1998-118615	A1	19980717 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-90110P	19970721 (60)
	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3832	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 16 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:205895 USPATFULL
TITLE: Methods and compositions for the regulation of
vasoconstriction
INVENTOR(S): Waeber, Christian, Boston, MA, United States
Moskowitz, Michael A., Belmont, MA, United States
Yoshimura, Shin-Ichi, Zurich, Switzerland
Salomone, Salvatore, Somerville, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041688	A1	20011115
APPLICATION INFO.:	US 2001-804987	A1	20010313 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-188859P	20000313 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Edward R. Gates, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210-2211	
NUMBER OF CLAIMS:	85	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2803	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 17 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2001:95472 USPATFULL
TITLE: Compositions, kits, apparatus, and methods for
inhibiting cephalic inflammation
INVENTOR(S): Levin, Bruce H., Philadelphia, PA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001004644	A1	20010621
APPLICATION INFO.:	US 2000-737302	A1	20001215 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-118615, filed on 17 Jul 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-170817P	19991215 (60)
	US 1997-90110P	19970721 (60)
	US 1998-72845P	19980128 (60)
	US 1998-84559P	19980506 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	4241	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L47 ANSWER 18 OF 24 USPATFULL on STN

ACCESSION NUMBER: 2000:64320 USPATFULL
TITLE: Preemptive prophylaxis of migraine device and method
INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, United
States 65721
Farmer, Kathleen U., 225 Finley Dr., Ozark, MO, United
States 65721

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066092		20000523
APPLICATION INFO.:	US 1998-185310		19981103 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64879P	19971106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	O'Connor, Cary	
ASSISTANT EXAMINER:	Natnithithadha, Navin	
LEGAL REPRESENTATIVE:	Husch & Eppenberger, LLC, Muir, Robert E.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	313	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 19 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1999:132801 USPATFULL

TITLE: Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine

INVENTOR(S): Armellino, Joseph, Chester, NJ, United States
Koslo, Randy, West Windsor Township, NJ, United States

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972916		19991026
APPLICATION INFO.:	US 1998-21284		19980210 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-52426P	19970714 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Zeller, Charles J., Savitsky, Thomas R.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1166	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 20 OF 24 USPATFULL on STN

ACCESSION NUMBER: 1998:4633 USPATFULL

TITLE: Methods of use and compositions of R(-) fluoxetine

INVENTOR(S): Young, James W., Palo Alto, CA, United States
Barberich, Timothy J., Concord, MA, United States
Teicher, Martin H., Wellesley, MA, United States

PATENT ASSIGNEE(S): Sepracor Inc., Marlborough, MA, United States (U.S. corporation)
McLean Hospital, Belmont, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5708035		19980113
APPLICATION INFO.:	US 1995-446348		19950522 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-80374, filed on 18 Jun		

1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-650385, filed on 4 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-793062, filed on 15 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-794264, filed on 15 Nov 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 21 OF 24 USPATFULL on STN

ACCESSION NUMBER: 97:61727 USPATFULL

TITLE: Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor

INVENTOR(S): Young, James W., Palo Alto, CA, United States
Barberich, Timothy J., Concord, MA, United States

PATENT ASSIGNEE(S): Teicher, Martin H., Wellesley, MA, United States
Sepracor Inc., Marlborough, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648396		19970715
APPLICATION INFO.:	US 1995-486056		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-80374, filed on 18 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-650385, filed on 4 Feb 1991, now abandoned Ser. No. Ser. No. US 1991-793062, filed on 15 Nov 1991, now abandoned And Ser. No. US 1991-794264, filed on 15 Nov 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 932

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 22 OF 24 USPATFULL on STN

ACCESSION NUMBER: 96:120921 USPATFULL

TITLE: Method for treating migraine headaches using optically pure S(+) fluoxetine

INVENTOR(S): Young, James W., Palo Alto, CA, United States
Barberich, Timothy J., Concord, MA, United States

PATENT ASSIGNEE(S): Sepracor Inc., Marlborough, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589511		19961231
APPLICATION INFO.:	US 1994-228240		19940415 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-67380, filed on 26 May 1993, now abandoned And Ser. No. US 1991-793036, filed on 15 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-566655, filed on 13 Aug 1990, now patented, Pat. No. US 5104899, said Ser. No. US -67380 which is a division of Ser.		

No. US -793036
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 23 OF 24 USPATFULL on STN
ACCESSION NUMBER: 93:82846 USPATFULL
TITLE: Method alleviating migraine headache with mast cell
degranulation blocking agents
INVENTOR(S): Theoharides, Theoharis C., Brooklhne, MA, United States
PATENT ASSIGNEE(S): KOS Pharmaceuticals, Inc., Miami, FL, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5250529		19931005
APPLICATION INFO.:	US 1991-815124		19911227 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-478164, filed on 8 Feb 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Waddell, Frederick E.		
ASSISTANT EXAMINER:	Weddington, K.		
LEGAL REPRESENTATIVE:	Foley & Lardner		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	705		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 24 OF 24 USPATFULL on STN
ACCESSION NUMBER: 93:74331 USPATFULL
TITLE: Treating classic migraine
INVENTOR(S): Goldberg, Arthur H., Montclair, NJ, United States
Lachman, Leonard, Fort Salonga, NY, United States
PATENT ASSIGNEE(S): Rugby-Darby Group Companies, Inc., Rockville Centre,
NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5242949		19930907
APPLICATION INFO.:	US 1992-850566		19920313 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Waddell, Frederick E.		
ASSISTANT EXAMINER:	Weddington, K.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	371		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.